X0206 3 2019-06-27 0 0001771917 Karuna Therapeutics, Inc. KRTX 0001237564 PAUL STEVEN M C/O KARUNA THERAPEUTICS, INC. 33 ARCH STREET, SUITE 3110 BOSTON MA 02110 1 1 0 0 President & CEO Stock Option (Right to Buy) 0.11 2021-03-04 Common Stock 292207 D Stock Option (Right to Buy) 7.04 2028-04-30 Common Stock 64466 D Stock Option (Right to Buy) 7.04 2028-04-30 Common Stock 71628 D Stock Option (Right to Buy) 7.27 2028-08-09 Common Stock 784555 D Stock Option (Right to Buy) 9.20 2029-03-21 Common Stock 449463 D Stock Option (Right to Buy) 9.20 2029-03-29 Common Stock 87494 D Stock Option (Right to Buy) 9.20 2029-04-08 Common Stock 15205 D Series A Preferred Stock Common Stock 96485 D This option is fully vested and exercisable as of the date hereof. This option shall vest and become exercisable in six equal semi-annual installments on each six month anniversary of February 28, 2018. This option (the "Initial Option Grant") shall vest and become exercisable in thirty monthly installments on each one month anniversary of June 15, 2018. An additional 274,594 shares vested upon closing of the Series B financing by Karuna Therapeutic, Inc. (the "Company") in March 2019. Upon the closing of the Company's initial public offering, an additional 50% of those shares that remain unvested will vest and become exercisable. Vests concurrently with the Initial Option Grant, as described in footnote 3. At time of each grant, 65% of the shares underlying the grant were vested, with the remaining vesting concurrently with the Initial Option Grant. The Series A Preferred Stock is convertible on a 1.2987-for-one basis into the number of shares of Common Stock shown in Column 3. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Preferred Stock has no expiration date. Exhibit 24 - Power of Attorney /s/ Steven Paul 2019-06-27